Loading…
Gaudium IVF and Women Health (GAUDIUMIVF)₹106.44−0.29%Healthcare Service Provider
In the Jun 2026 quarter (consolidated), Gaudium IVF and Women Health reported sales of ₹19.36 Cr, up 9.1% from Jun 2025, and net profit of ₹1.79 Cr, down 41.9% year on year. For the year to Mar 2026, sales were ₹104 Cr and net profit ₹24.05 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 14.41 | 26.89 | 17.74 | 31.68 | 24.48 | 30.33 | 19.36 |
| Expenses | 8.74 | 18.14 | 12.58 | 17.92 | 17.90 | 18.13 | 16.91 |
| Operating Profit | 5.67 | 8.73 | 5.16 | 13.79 | 6.57 | 12.19 | 2.44 |
| OPM % | 39.2% | 32.4% | 29.0% | 43.4% | 26.8% | 40.1% | 12.6% |
| Other Income | 0.00 | 0.24 | 0.00 | 0.16 | 0.11 | 0.19 | 1.13 |
| Interest | 0.38 | 0.42 | 0.49 | 0.50 | 1.19 | 1.28 | 0.37 |
| Depreciation | 0.57 | 0.35 | 0.60 | 0.60 | 0.48 | 0.63 | 0.71 |
| Profit before tax | 4.67 | 8.13 | 4.02 | 12.74 | 4.95 | 10.38 | 2.44 |
| Tax % | 27.7% | 21.0% | 24.0% | 26.6% | 27.0% | 19.8% | 27.8% |
| Net Profit | 3.41 | 6.47 | 3.08 | 9.40 | 3.64 | 8.38 | 1.79 |
| EPS (Rs) | 0.54 | 1.04 | 0.49 | 1.52 | 0.58 | 1.14 | 0.23 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 36.98 | 43.97 | 47.93 | 70.91 | 104 | 106 |
| Expenses | 22.93 | 23.93 | 27.91 | 41.87 | 66.82 | 70.86 |
| Operating Profit | 14.01 | 20.03 | 19.03 | 29.03 | 38.05 | 34.99 |
| OPM % | 37.0% | 46.0% | 41.0% | 41.0% | 36.0% | 33.1% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.59 |
| Interest | 0.99 | 0.00 | 0.99 | 1.99 | 2.99 | 3.34 |
| Depreciation | 0.99 | 0.99 | 1.99 | 1.99 | 2.99 | 2.42 |
| Profit before tax | 11.96 | 17.93 | 16.92 | 24.92 | 31.87 | 30.51 |
| Tax % | 26.0% | 26.0% | 38.0% | 25.0% | 24.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | −0.02 | — |
| Net Profit | 9.01 | 14.02 | 10.01 | 19.04 | 24.05 | 23.21 |
| EPS (Rs) | 88.86 | 136.04 | 103.90 | 3.11 | 3.35 | 3.47 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 0.99 | 31.04 | 36.07 |
| Reserves | 8.03 | 22.07 | 26.09 | 16.04 | 116 |
| Borrowings | 6.01 | 12.02 | 17.05 | 21.03 | 25.04 |
| Other Liabilities | 3.01 | 2.01 | 7.03 | 22.10 | 16.08 |
| Total Liabilities | 18.05 | 37.10 | 51.17 | 89.21 | 194 |
| Fixed Assets | 4.01 | 18.07 | 19.07 | 18.04 | 30.10 |
| CWIP | 0.00 | 0.00 | 0.00 | 6.99 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 5.01 | 5.01 |
| Other Assets | 14.04 | 18.03 | 32.10 | 58.17 | 158 |
| Inventories | 0.00 | 1.99 | 1.99 | 6.99 | 3.99 |
| Trade receivables | 6.01 | 1.01 | 14.01 | 33.03 | 53.10 |
| Cash & equivalents | 2.01 | 15.05 | 12.04 | 7.02 | 9.04 |
| Total Assets | 18.05 | 37.10 | 51.17 | 89.21 | 194 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | −0.99 | 23.96 | 2.99 | 8.98 | 6.98 |
| Cash from investing activity | −0.99 | −15.98 | −4.99 | −14.98 | −87.85 |
| Cash from financing activity | 3.01 | 5.01 | −1.01 | 2.01 | 82.09 |
| Net cash flow | 0.00 | 13.01 | −2.99 | −4.99 | 1.99 |
| Capex | 0.99 | 14.97 | 2.99 | 8.99 | 1.99 |
| Free cash flow | −2.01 | 9.01 | 1.01 | 0.00 | 5.01 |
| CFO / OP % | 13.0% | 141.0% | 27.0% | 46.0% | 51.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 66 | 9 | 105 | 171 | 188 |
| Inventory days | 29 | 111 | 168 | 175 | 38 |
| Days payable | 115 | 78 | 63 | 339 | 134 |
| Cash conversion cycle | −20 | 41 | 210 | 7 | 92 |
| Working capital days | 62 | −51 | −14 | 45 | 92 |
| ROCE % | — | 75.9% | 44.9% | 48.9% | 28.9% |
For the Jun 2026 quarter, Gaudium IVF and Women Health reported sales of ₹19.36 Cr, up 9.1% year on year and net profit of ₹1.79 Cr, down 41.9% year on year. The operating margin was 12.6%.
Gaudium IVF and Women Health's sales for the year to Mar 2026 were ₹104 Cr; over the last twelve months they were ₹106 Cr.
Net profit for the year to Mar 2026 was ₹24.05 Cr, and ₹23.21 Cr over the last twelve months. Earnings per share over the same trailing period were ₹3.47.
Gaudium IVF and Women Health reported borrowings of ₹25.04 Cr at Mar 2026, against cash and equivalents of ₹9.04 Cr.
Cash from operations was ₹6.98 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹5.01 Cr.